Levine M N
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Clin Chest Med. 1995 Jun;16(2):321-8.
There is renewed interest in the treatment of acute deep vein thrombosis and acute pulmonary embolism with thromboembolytic therapy because of the demonstrated mortality reduction in patients with acute myocardial of the demonstrated mortality reduction in patients with acute myocardial infarction and because of the development of newer, fibrin-specific drugs. Bleeding is the major complication of thrombolytic therapy. This article addresses the benefits and risks of using thrombolytic therapy in patients with acute deep vein thrombosis or acute pulmonary embolism.
由于已证实溶栓治疗可降低急性心肌梗死患者的死亡率，且新型纤维蛋白特异性药物不断涌现，人们对使用溶栓疗法治疗急性深静脉血栓形成和急性肺栓塞重新产生了兴趣。出血是溶栓治疗的主要并发症。本文探讨了在急性深静脉血栓形成或急性肺栓塞患者中使用溶栓疗法的益处和风险。
